Live price temporarily unavailable.
HCW Biologics (HCWB) is a Health Care company. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $4.10M | $0 | $6.72M | $2.84M | $2.57M | $54.2K |
| Growth (year over year) | — | −100.0% | — | −57.7% | −9.7% | −97.9% |
| Gross profit | — | $0 | $2.59M | $560.4K | $959.4K | $10.8K |
| Gross margin | — | — | 38.5% | 19.7% | 37.4% | 20.0% |
| Operating income | −$5.82M | −$13.4M | −$15.1M | −$25.7M | −$29.5M | −$13.2M |
| Operating margin | −142.1% | — | −224.3% | −905.0% | −1147.6% | −24270.7% |
| Net income | −$5.80M | −$12.9M | −$14.9M | −$25.0M | −$30.0M | −$7.96M |
| Net margin | −141.5% | — | −221.7% | −879.5% | −1169.7% | −14677.1% |
| EPS (diluted) | −$85824.00 | −$165.60 | −$100.80 | −$168.00 | −$185.76 | −$63.78 |
| Balance sheet | ||||||
| Cash and equivalents | $8.46M | $11.7M | $22.3M | $3.60M | $4.67M | $1.95M |
| Total assets | $15.4M | $53.5M | $46.8M | $28.5M | $30.2M | $24.5M |
| Total liabilities | $32.1M | $2.32M | $9.38M | $15.1M | $37.0M | $21.8M |
| Long-term debt | — | $0 | $6.41M | $6.30M | $7.38M | $0 |
| Shareholders' equity | −$16.7M | $51.2M | $37.4M | $13.5M | −$6.77M | $2.76M |
| Cash flow | ||||||
| Operating cash flow | −$10.4M | −$11.0M | −$10.4M | −$22.5M | −$14.2M | −$13.4M |
| Capital expenditure | $186.7K | $47.3K | $10.3M | $6.20M | $261.6K | $0 |
| Free cash flow | −$10.6M | −$11.0M | −$20.7M | −$28.7M | −$14.5M | −$13.4M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $426.4K | $394.8K | $5.07K | $6.55K | $15.6K | — | $6.54M | $135.6K |
| Growth (year over year) | −50.0% | — | −99.6% | −98.9% | −96.3% | — | +129080.7% | +1969.7% |
| Gross profit | $85.3K | $79.0K | $1.01K | $1.31K | $3.12K | — | $6.53M | −$93.9K |
| Gross margin | 20.0% | 20.0% | 20.0% | 20.0% | 20.0% | — | 99.8% | −69.3% |
| Operating income | −$3.68M | −$3.14M | −$1.97M | −$3.46M | −$3.29M | — | $3.24M | −$3.17M |
| Operating margin | −864.1% | −795.9% | −38811.5% | −52886.7% | −21095.3% | — | 49.5% | −2335.6% |
| Net income | −$3.90M | −$3.37M | −$2.20M | −$1.93M | −$4.55M | — | $3.47M | −$5.22M |
| Net margin | −915.1% | −854.4% | −43373.6% | −29431.0% | −29183.2% | — | 53.1% | −3849.9% |
| EPS (diluted) | −$24.78 | −$16.02 | −$11.80 | −$40.72 | −$12.12 | — | $1.39 | −$11.58 |
| Balance sheet | ||||||||
| Cash and equivalents | $998.2K | $4.67M | $1.11M | $2.44M | $1.10M | $1.95M | $1.23M | $741.3K |
| Total assets | $26.6M | $30.2M | $26.3M | $28.9M | $25.4M | $24.5M | $27.3M | $26.8M |
| Total liabilities | $36.5M | $37.0M | $34.8M | $29.0M | $27.6M | $21.8M | $21.6M | $19.3M |
| Long-term debt | $6.46M | $7.38M | $7.71M | $367.2K | $0 | $0 | — | — |
| Shareholders' equity | −$9.97M | −$6.77M | −$8.56M | −$52.0K | −$2.11M | $2.76M | $5.76M | $7.43M |
| Cash flow | ||||||||
| Operating cash flow | −$2.93M | −$2.83M | −$3.51M | −$3.28M | −$3.24M | — | −$1.58M | −$3.97M |
| Capital expenditure | $37.1K | $113.4K | $0 | $0 | $0 | — | — | — |
| Free cash flow | −$2.96M | −$2.95M | −$3.51M | −$3.28M | −$3.24M | — | — | — |
From HCW Biologics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning HCW Biologics in our feed yet.